KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Long-Term Investments (2018 - 2019)

Historic Long-Term Investments for Travere Therapeutics (TVTX) over the last 3 years, with Q2 2019 value amounting to $15.0 million.

  • Travere Therapeutics' Long-Term Investments changed 0.0% to $15.0 million in Q2 2019 from the same period last year, while for Jun 2019 it was $15.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $15.0 million for FY2018, which is N/A changed from last year.
  • Travere Therapeutics' Long-Term Investments amounted to $15.0 million in Q2 2019, which was down 0.0% from $15.0 million recorded in Q1 2019.
  • Travere Therapeutics' Long-Term Investments' 5-year high stood at $15.0 million during Q1 2018, with a 5-year trough of $15.0 million in Q1 2018.